Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., July 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows:
Conference call details: | |
Date: | August 5, 2021 |
Time: | 4:30 p.m. U.S. Eastern Time (ET) |
Dial-in number: | (866) 652-5200 (Domestic) or (412) 317-6060 (International) |
Webcast: | |
• Participants will be prompted to request to join the Novavax, Inc. call. | |
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast. | |
Replay details: | |
Date: | Available starting at 7:30 p.m. ET, August 5, 2021 |
Dial-in number: | (877) 344-7529 (Domestic) or (412) 317-0088 (International) |
Passcode: | 10158313 |
Webcast: | www.novavax.com/events, until November 12, 2021 |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts:
InvestorsNovavax, Inc. Erika Schultz | 240-268-2022[email protected]
Solebury TroutAlexandra Roy | 617-221-9197[email protected]
MediaAlison Chartan | 240-720-7804Laura Keenan | 202-709-7521[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operational-highlights-on-august-5-2021-301325648.html
SOURCE Novavax, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RH touts 'exceptional' demand for new collections after Q4 results fall short
- New Oriental to Report Third Quarter 2024 Financial Results on April 24, 2024
- Invitation: Presentation of Sandvik's report of the first quarter 2024
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!